Highlights

  • Aroa Biosurgery received confirmation that CMS intends to maintain the current outpatient skin substitute payment framework for Calendar Year 2027.
  • Symphony remains covered under the outpatient reimbursement structure with a proposed payment rate of US$127.14 per square centimetre.
  • Aroa reported FY2026 Revenue of NZ$104 million, up 23% on the prior year, with normalised EBITDA of NZ$13 million.
  • The company continues to progress Symphony clinical evidence development ahead of expected trial publication in FY2027.

Aroa Biosurgery (ASX:ARX) has secured further visibility around the U.S. reimbursement environment for its Symphony wound-care product, with the Centers for Medicare & Medicaid Services (CMS) proposing to maintain the existing outpatient skin substitute payment framework through Calendar Year 2027.

The announcement, made on 14 July 2026, confirms CMS intends to continue the current single payment rate of US$127.14 per square centimetre for outpatient skin substitutes rather than revising the framework introduced from January 2026.

The update does not represent a new product approval or a sales milestone, but it provides additional clarity around reimbursement conditions for Symphony as Aroa (ASX:ARX) continues to develop its U.S. outpatient wound-care presence.

What Was Announced?

Aroa confirmed that CMS has proposed maintaining the existing outpatient skin substitute payment structure for CY2027. The framework, introduced from January 2026, applies a single flat payment rate of US$127.14 per square centimetre across outpatient settings.

The revised structure replaced a previous reimbursement model where payment levels varied significantly between products. The updated framework was introduced as part of CMS changes aimed at creating a more consistent reimbursement approach for skin substitute products.

The proposal directly affects Symphony, Aroa's wound-care device used in outpatient hospital and clinic settings for hard-to-heal wounds including diabetic foot ulcers and venous leg ulcers.

Myriad, Aroa's other major commercial product, operates under a separate inpatient reimbursement framework and was not affected by this specific CMS decision.

The company stated that the proposed framework provides additional clarity during a period of change in the outpatient skin substitute market.

Why This Matters

The U.S. skin substitute reimbursement market has undergone significant changes, with CMS moving from product-specific reimbursement variations toward a standardised payment approach.

For Aroa (ASX:ARX), maintaining the existing reimbursement rate provides greater visibility for Symphony's commercial development strategy in U.S. outpatient settings. A stable reimbursement environment may support discussions with hospitals and clinics evaluating wound-care solutions.

However, the update should be viewed as continuation of an existing reimbursement structure rather than a new coverage expansion. The CMS announcement remains a proposed framework and does not represent additional reimbursement approval.

The company's ability to convert reimbursement clarity into Symphony adoption will depend on clinical evidence, clinician engagement, distribution and commercial execution.

Company Background

Aroa Biosurgery (ASX:ARX) is a New Zealand-based regenerative medicine company focused on soft-tissue repair products derived from ovine forestomach extracellular matrix technology.

The company develops biological devices designed for wound healing and tissue repair applications. Its two main commercial products are Myriad, primarily used in hospital operating rooms, and Symphony, focused on outpatient treatment of chronic wounds.

Aroa has stated that its products have been used in more than 7 million procedures globally.

Symphony has had a smaller U.S. outpatient presence compared with Myriad, and the company has been developing clinical evidence through a randomised controlled trial in diabetic foot ulcer patients. Aroa expects full publication of trial results in the third quarter of FY2027.

Financial Position

Aroa reported FY2026 revenue of NZ$104 million, representing a 23% increase compared with the prior year, or 21% growth on a constant currency basis.

Normalised Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) was NZ$13 million, exceeding the company's guidance range and representing the second consecutive year of positive normalised EBITDA.

Myriad was the primary contributor to revenue growth, with product revenue increasing 54% and representing 59% of group revenue through direct channels.

Aroa held NZ$27 million in cash at the end of FY2026 and generated approximately NZ$5 million in net cash during the year.

What Comes Next?

The CMS CY2027 reimbursement proposal remains subject to finalisation. Confirmation of the framework would provide Aroa with a more predictable reimbursement environment while it continues to pursue Symphony adoption in U.S. outpatient settings.

The next major product-related milestone is the expected publication of Symphony randomised controlled trial results in diabetic foot ulcers during the third quarter of FY2027.

Alongside Symphony development, Myriad adoption within U.S. hospital operating rooms remains an important near-term commercial focus for Aroa (ASX:ARX), with future updates expected around operational performance and FY2027 progress.

Risks

The CMS reimbursement framework remains a proposal and could change before final implementation or in future policy reviews. Aroa also faces competition from larger wound-care companies operating in the U.S. market. Symphony's outpatient adoption remains dependent on clinical evidence, clinician acceptance, distribution and commercial execution. Currency movements between the New Zealand dollar and U.S. dollar may also affect reported financial results due to Aroa's international revenue exposure.

Investor Takeaway

The CMS reimbursement update provides Aroa (ASX:ARX) with additional visibility around the payment environment supporting Symphony's U.S. outpatient opportunity. However, the announcement represents continuation of an existing reimbursement framework rather than a new reimbursement expansion.

The more important upcoming milestones remain the publication of Symphony clinical trial results and the company's ability to translate reimbursement stability into broader adoption. Myriad's continued commercial performance and future FY2027 updates will also remain relevant factors for investors monitoring Aroa's progress.